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ABSTRACT
Objective To evaluate and compare the efficacy and
safety of bronchodilators and steroids, alone or
combined, for the acute management of bronchiolitis in
children aged less than 2 years.
Design Systematic review and meta-analysis.
Data sources Medline, Embase, Central, Scopus,
PubMed, LILACS, IranMedEx, conference proceedings,
and trial registers.
InclusioncriteriaRandomisedcontrolledtrialsofchildren
aged 24 months or less with a first episode of
bronchiolitis with wheezing comparing any
bronchodilator or steroid, alone or combined, with
placebo or another intervention (other bronchodilator,
other steroid, standard care).
Review methods Two reviewers assessed studies for
inclusion and risk of bias and extracted data. Primary
outcomes were selected by clinicians a priori based on
clinicalrelevance:rateofadmissionforoutpatients(day1
and up to day 7) and length of stay for inpatients. Direct
meta-analyses were carried out using random effects
models. A mixed treatment comparison using a Bayesian
network model was used to compare all interventions
simultaneously.
Results 48 trials (4897 patients, 13 comparisons) were
included. Risk of bias was low in 17% (n=8), unclear in
52% (n=25), and high in 31% (n=15). Only adrenaline
(epinephrine) reduced admissions on day 1 (compared
with placebo: pooled risk ratio 0.67, 95% confidence
interval 0.50 to 0.89; number needed to treat 15, 95%
confidence interval 10 to 45 for a baseline risk of 20%;
920 patients). Unadjusted results from a single large trial
with low risk of bias showed that combined
dexamethasone and adrenaline reduced admissions on
day 7 (risk ratio 0.65, 0.44 to 0.95; number needed to
treat 11,7 to 76 fora baseline risk of 26%;400 patients).
A mixed treatment comparison supported adrenaline
alone or combined with steroids as the preferred
treatments for outpatients (probability of being the best
treatment based on admissions at day 1 were 45% and
39%, respectively). The incidence of reported harms did
not differ. None of the interventions examined showed
clear efficacy for length of stay among inpatients.
Conclusions Evidence shows the effectiveness and
superiority of adrenaline for outcomes of most clinical
relevance among outpatients with acute bronchiolitis,
and evidence from a single precise trial for combined
adrenaline and dexamethasone.
INTRODUCTION
Bronchiolitis is the most common disease of the lower
respiratory tract during the first year of life.
1 Respira-
tory syncytial virus is the underlying cause of most
bronchiolitis and this infection is associated with sub-
stantial morbidity in young children.
23 Ongoing
research in bronchiolitis reflects both the burden of
disease in developed and developing countries and a
lack of clear evidence for its therapeutic
management.
45Previous studies have shown substan-
tial variation in the management of acute bronchiolitis
throughout the world, including the use of different
bronchodilators(β2agonists,adrenaline(epinephrine),
anticholinergics)andsteroids.
6-9Someofthisvariation
may be attributable to varying severity of disease or to
different care settings and geographical location.
Several systematic reviews have assessed various
treatments, including β2 agonists and anticholinergics,
adrenaline, corticosteroids, hypertonic saline, anti-
biotics, surfactant, ribavirin, and chest physiotherapy.
10
These reviews have failed to provide convincing evi-
dence to support any of these treatments in the acute
management of bronchiolitis, and their routine use is
not recommended by current clinical practice
guidelines.
11-13 Despite implementation of these guide-
lines, bronchodilators especially are still frequently
used.
1415
A 2003 report recommended rigorously designed,
adequately sized randomised controlled trials on
treatmentsthatshowedsomepotentialforbeingeffica-
cious, including nebulised bronchodilators (adrena-
line, salbutamol, or ipratropium bromide, alone or
combined), oral or parenteral corticosteroids (prefer-
entially dexamethasone), and inhaled corticosteroids
(especially budesonide).
4 Two large trials examining
some of these interventions have recently been com-
pleted.Thelargesttrialeverpublishedinthisarea,con-
cerning800childreninCanada,usedafactorialdesign
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BMJ | ONLINE FIRST | bmj.com page 1 of 10to examine adrenaline and dexamethasone, alone or
combined, compared with placebo.
16 Another trial
completedconcurrentlyintheUnitedStatescompared
dexamethasone with placebo in a sample of 600
children.
17 These two large trials add substantially to
the evidence and provide a strong signal for further
synthesis work.
18
Theserecenttrialsalsoraisenewquestionsandpoten-
tially novel approaches to the acute management of
bronchiolitis that warrant closer investigation. Specifi-
cally,onetrialshoweda35%relativereductiononrates
of admission to hospital with combined adrenaline and
dexamethasone treatment compared with placebo.
16
Previously,asmallertrialwasthefirsttoshowtheeffec-
tiveness of oral dexamethasone in reducing hospital
admissions in outpatients with acute bronchiolitis.
19
The unique feature of this trial, among others that did
notshoweffectiveness,wasthathighdosesteroidswere
administered along with a bronchodilator (salbutamol)
accordingtoadefinedprotocolratherthanatthediscre-
tionoftheattendingphysician.Althoughtheinteractive
effect of steroids and bronchodilators has emerged as a
potentialtreatmentoption,
16ithasnotbeenexaminedat
the level of systematic review and placed in the context
of other evidence.
Drivenbyrecentevidenceandcurrentuncertainties
inpractice,we systematicallyevaluatedandcompared
the efficacy and safety of bronchodilators (β2 agonists,
adrenaline, anticholinergics) and steroids, alone or
combined, for the acute management of bronchiolitis.
Wealsodeterminedtheeffectivenessofsteroidswitha
fixed protocol for bronchodilator use compared with
those in which the bronchodilator was givenat the dis-
cretionoftheattendingphysician,andbronchodilators
givenwithandwithoutsteroids.Bycarryingoutmixed
treatment comparisons, we sought to improve on pre-
vious systematic reviews that focused primarily on
pairwise, direct comparisons, often with the compara-
tor beinga placebo.Mixed treatmentanalysisis a rela-
tively new development in the area of evidence
synthesis,withtheadvantageofcombiningdataondif-
ferent interventions for the same condition.
2021
METHODS
Throughallstagesofthiswork,wefollowedaprotocol
thatwasdevelopedby the coauthorsbeforethe review
began, in which all outcomes and analyses were speci-
fied a priori.
Search strategy
A medical research librarian searched Medline Ovid
version (1950 to November week 2, 2009), Embase
Ovid version (1980 to 2009 week 47), EBM Reviews
—Cochrane Central Register of Controlled Trials (4th
quarter 2009), LILACS—Latin American and Carib-
bean Center on Health Sciences Information (25
November 2009), PubMed (9 March 2009), Scopus
(1823 to 25 November 2009), and IranMedEx (26
November 2009). (See web extra appendix A for the
search strings.) We applied no restrictions on year or
language. To identify unpublished studies and studies
in progress, we searched conference proceedings for
Records identified through database searches (n=2249)
Potentially relevant studies assessed for eligibility (n=348)
Primary studies included in review (n=48*)
Comparisons with active control Comparisons with placebo
Steroid v salbutamol (n=1) Steroid v adrenaline (n=2†)
Records excluded (n=1905)
Studies identified through handsearching
and reference checking (n=4)
Excluded studies (n=300):
  Publication type (n=132)
  Population (n=88)
  Study design (n=45)
* Some studies deal with more than one comparison
† Comparisons include studies with and without use of bronchodilators or steroids that followed a protocol
Duplicate publications (n=8)
Interventions (n=14)
Unobtainable (n=13)
Salbutamol v
ipratropium (n=4)
Adrenaline v
salbutamol (n=14)
Steroid and salbutamol v
adrenaline (n=2)
Adrenaline and
dexamethasone
v salbutamol (n=1)
Adrenaline v placebo (n=8†) Steroid v placebo (n=17†)
Ipratropium v
placebo (n=4†)
Salbutamol or terbutaline
v placebo (n=20†)
Steroid and salbutamol
v placebo (n=1)
Ipratropium and salbutamol
v placebo (n=1)
Adrenaline and
dexamethasone
v placebo (n=1)
Fig 1 | Flow diagram for study selection
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ters (see web extra appendix A). Finally, we checked
reference lists of relevant studies and previous reviews
and contacted experts in the specialty.
Study selection
Studies were included if they were randomised con-
trolled trials, involved inpatients or outpatients aged
24 months or less with bronchiolitis, and compared a
bronchodilator (salbutamol or terbutaline, adrenaline,
ipratropium bromide) or steroid (inhaled or systemic),
or both combined, with another intervention (either
placebo or another intervention including another
bronchodilator or steroid). Bronchiolitis was defined
as a physician diagnosed first episode of acute wheez-
ing with respiratory distress and associated with
clinical evidence of viral infection. We excluded stu-
dies in which any participants had a history of wheez-
ing, respiratory distress, or a formal diagnosis of
asthma. We chose to focus on first episodes of wheez-
ing to deal with the possible overlap between bronch-
iolitis, recurrent wheezing, and asthma. We also
excluded studies in the intensive care setting or with
intubated or ventilated participants, and studies asses-
sing longer courses of steroids started during the acute
phase of bronchiolitis for the prevention of post-
bronchiolitic wheezing. The primary outcomes,
selected by the clinician authors a priori based on clin-
icalrelevance,wererateofadmissionsatday1andday
7foroutpatientstudiesandlengthofstayinhospitalfor
inpatient studies. Secondary outcomes included
changeinclinicalscore,oxygensaturation,respiratory
Table 1 |Overview of studies included in systematic review
Comparison by population
No of studies
(Noofpatients)
No of studies
providing data
for primary outcome
Years of publication
(median) Countries of study Risk of bias
Steroid v placebo:
Inpatients 9 (772) 8 1996-2007 (2000) UK (2), Israel, Belgium, Mexico, Canada,
Thailand, Brazil, USA
1low,4unclear,4high
Outpatients 8 (1778) 8 1998-2009 (2002/2004) USA (2), Canada (2), Turkey (2), Israel,
Paraguay
1low,4unclear,3high
Adrenaline v placebo:
Inpatients 3 (330) 2 2002-3 (2002) England, Canada, Australia 1low,1unclear,1high
Outpatients 5 (526) 4 1995-2009 (2005) Turkey (2), Iran, Canada, USA 2low,2unclear,1high
Salbutamol* or terbutaline v placebo:
Inpatients: 9 (488) 6 1991-2009 (1997) Turkey (2),France, SaudiArabia,Singapore,
Canada, USA, Tunisia, Australia
1low,5unclear,3high
Outpatients 11 (926) 6 1990-2008 (1998) Canada(3),Turkey(3),USA(2),Egypt,India,
Iran
2low,6unclear,3high
Ipratropium v placebo:
Inpatients 3 (194) 2 1995-2008 (1997) Saudi Arabia, Singapore, Turkey 3 unclear
Outpatients 1 (72) 1 1992 Canada 1 unclear
Adrenaline and dexamethasone v other:
Inpatients 0 NA NA NA NA
Outpatients 2 (436) 2 2004, 2009 Turkey, Canada 1 low, 1 high
Ipratropium and salbutamol* v placebo:
Inpatients 0 NA NA NA NA
Outpatients 1 (72) 1 1992 Canada 1 unclear
Steroid v adrenaline:
Inpatients 0 NA NA NA NA
Outpatients 2 (444) 2 1995, 2009 Turkey, Canada 1 low, 1 high
Adrenaline v salbutamol*:
Inpatients 6 (433) 4 1993-2007 (2001/2002) Canada (2), Jordan, Chile, Iran, India 1low,3unclear,2high
Outpatients 8 (378) 6 1995-2007 (2004) Turkey (3), USA (2), Israel, Iran, Canada, 4low,3unclear,1high
Steroid v salbutamol*:
Inpatients 0 NA NA NA NA
Outpatients 1 (45) 1 1995 Turkey 1 high
Salbutamol v ipratropium:
Inpatients 4 (192) 3 1995-2008 (2000) Saudi Arabia, Singapore, Turkey (2) 3 unclear, 1 high
Outpatients 0 NA NA NA NA
Steroid and salbutamol* v other:
Inpatients 0 NA NA NA NA
Outpatients 2 (103) 2 1998, 2004 Turkey (2) 2 high
NA=Not applicable.
*Salbutamol has been used throughout to also refer to albuterol.
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return visits to the emergency department or any
healthcare provider; and harms or adverse events.
Tworeviewersindependentlyscreenedthetitlesand
abstracts to determine if an article met the inclusion
criteria. The full text of studies classified as “relevant”
or “unclear” were assessed independently by two
reviewers using a standard form. Disagreements were
resolvedbyconsensusoradjudicationbyathirdparty.
Risk of bias assessment
Included studies were assessed using the Cochrane
Collaboration risk of bias tool.
22 The tool consists of
six domains (sequence generation, allocation
concealment, blinding, incomplete outcome data,
selective outcome reporting, and “other sources of
bias”). Blinding and incomplete outcome data were
assessed separately for the following types of out-
comes: administrative, clinical or respiratory scores
and other clinical variables, and others (for example,
adverse events).
Tworeviewersindependentlyassessedriskofbiasof
included studies. One reviewer assessed reports writ-
teninTurkish.Discrepancieswereresolvedbyconsen-
sus among three reviewers.
Data extraction
Data were extracted using a standardised form (avail-
able from authors) and entered into Microsoft Excel
(Microsoft, Redmond, WA). One reviewer extracted
dataandasecondreviewercheckedtheseforaccuracy
andcompleteness.Extracteddataincludedstudychar-
acteristics, inclusion and exclusion criteria, character-
isticsofparticipants,interventions(includingtheuseof
a fixed protocol for cointerventions), outcomes, and
results. Reviewers resolved discrepancies by consen-
sus or in consultation with a third party. All quantita-
tive data were checked by the statistician during
analysis.
Grading the body of evidence
Tworeviewersindependentlygradedthequalityofthe
body of evidence for the comparisons deemed most
clinically relevant. Assessments, based on a modified
GRADE approach, were completed for length of stay
and admissions, change in clinical score, and adverse
events.
2324 Domains examined were risk of bias, con-
sistency,directness,andprecision.Decisionruleswere
developed a priori based on clinical and methodologi-
cal relevance and are available on request. Discrepan-
cies were resolved through discussion. The overall
strength of evidence was graded as high, moderate,
low, or insufficient (see web extra appendix B).
Statistical analysis
We considered studies of inpatients and outpatients
separately, except for harms related data. Weighted
mean differences were used to pool continuous vari-
ables when the same measurement scale was used (for
example, heart rate) and standardised mean differ-
ences when different scales were used (for example,
clinical scores). For pairwise meta-analysis, we used
risk ratios to pool dichotomous variables. Data were
combined using the DerSimonian-Laird random
effects models
25 in Review Manager version 5.0
(Cochrane Collaboration, Copenhagen, Denmark).
Results are reported with 95% confidence intervals,
and statistical significance was set at P<0.05. Statistical
heterogeneity was quantified using the I
2 statistic. A
value greater than 50% was considered to be substan-
tial heterogeneity.
2627 We calculated numbers needed
totreatusingthefinalriskratiosandthesimpleaverage
baselineriskacrossallincludedtrials—thatis,thenum-
ber of events divided by the number of participants
Admissions day 1
  Steroid v placebo
  Steroid v adrenaline
  Steroid v salbutamol
  Adrenaline v placebo
  Adrenaline v salbutamol
  Salbutamol or terbutaline v placebo
  Ipratropium v placebo
  Adrenaline + steroid v placebo
  Salbutamol + steroid v placebo
  Salbutamol + steroid v adrenaline
Admissions day 7
  Steroid v placebo
  Steroid v adrenaline
  Adrenaline v placebo
  Adrenaline v salbutamol
  Salbutamol or terbutaline v placebo
  Adrenaline + steroid v placebo
0.92 (0.78 to 1.08)
1.12 (0.66 to 1.88)
1.00 (0.21 to 4.86)
0.67 (0.50 to 0.89)
0.65 (0.38 to 1.13)
0.78 (0.53 to 1.14)
1.56 (0.84 to 2.90)
0.65 (0.40 to 1.05)
0.67 (0.13 to 3.44)
5.00 (0.26 to 96.13)
0.86 (0.70 to 1.06)
1.08 (0.77 to 1.52)
0.78 (0.59 to 1.04)
1.03 (0.66 to 1.60)
1.03 (0.34 to 3.10)
0.65 (0.44 to 0.95)
8/1762
2/444
1/45
4/920
6/295
4/196
1/69
1/400
1/30
2/64
5/1530
1/399
1/800
1/63
2/259
1/400
0.1 0.2 0.5 1 25 10
Comparisons (A v B) Risk ratio
(95% CI)
Risk ratio
(95% CI)
No of studies/
No of patients
0
2
NA
0
48
0
NA
NA
NA
NA
31
NA
21
NA
0
NA
I2 (%)
Favours A Favours B
Fig 2 | Results from meta-analysis of direct comparisons for admission rates from emergency
department (day 1 and day 7) in outpatients. Only comparisons with quantitative results are
shown
Salbutamol
Placebo
Steroid
6
No of comparisons
5
4
3
2
1
Salbutamol
+ steroid
Ipratropium
+ salbutamol
Adrenaline
Adrenaline
+ steroid 1
1
1
1
1
1 2
3
Fig 3 | Comparisons (14 studies) contributing to mixed
treatment analysis for admissions at day 1. Numerals within
figure are studies at low risk of bias (four in total)
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computed numbers needed to treat using the mini-
mum and maximum baseline risk for the trials
included in the meta-analysis. In our main analysis,
for studies where groups received combined inter-
ventions that followed a protocol, we considered the
common intervention across groups to “cancel out.”
For example, to obtain an overall main effect we con-
sidered a study comparing combined steroid and
bronchodilator with bronchodilator alone in the com-
parison of steroid with placebo. Furthermore, two
groups from factorial trials could contribute to the
same analysis—for example, combined steroid and
placebo compared with combined placebo and pla-
cebo, and combined steroid and bronchodilator com-
pared with combined bronchodilator and placebo
would both contribute to the comparison of steroid
with placebo. The robustness of this assumption was
tested by carrying out subgroup analyses comparing
results in trials with cointerventions following a proto-
col versus trials with cointerventions at the discretion
ofthephysiciantoexplorepotentialadditive(synergis-
tic) or subtractive (antagonistic) effects. A priori we
planned to do sensitivity analyses based on risk of
bias (low v unclear or high).
For the primary outcomes we carried out a mixed
treatment analysis using a Bayesian network model to
compareallinterventionssimultaneouslyandtouseall
available information on treatment effects in a single
analysis.
212829 Mean differences or log odds ratios
were modelled using non-informative prior distribu-
tions. A normal prior distribution with mean 0 and
large variance (10000) was used for each of the trial
means or log odds ratios, whereas their between
study variance had a uniform prior with range 0 to 2
(admissions) or 0 to 10 (length of stay). These priors
were checked for influence with sensitivity analyses.
We carried out Markov Chain Monte Carlo simula-
tions using WinBugs software to obtain simultaneous
estimatesofallinterventionscomparedwithplaceboas
wellasestimatesofwhichinterventionswerethebest.
30
A burn-in sample of 20000 iterations was followed by
200000 iterations used to compute estimates. Results
arereportedwith95%credibilityintervals.Weconsid-
ered all trial groups separately in the analysis. For
example, a trial comparing steroid with placebo using
a fixed protocol for bronchodilator use in both arms
wouldcontributetwoarmstothemixedtreatmentana-
lysis: combined steroid and bronchodilator and
bronchodilator. Factorial trials contributed all four
groups, and correlation between groups in such trials
was factored into the computations. We checked the
analyses for consistency using cross validation of all
contrasts that had direct evidence.
31
RESULTS
Figure1showstheflowofstudiesthroughtheselection
process. Forty eight studies totalling 4897 patients
were included (see web extra appendix C). Table 1
shows the comparisons made, the number of studies
foreachcomparisonbyinpatientandoutpatientpopu-
lation,thenumberofstudiesthatprovideddataforour
primary outcomes, the years of publication, and coun-
try of study. The drugs were administered in a variety
of ways and varied across studies and interventions:
corticosteroids –systemic (oral, intravenous, or intra-
muscular) or nebulised; adrenaline –nebulised; and
bronchodilators –mostly nebulised. The risk of bias
was low for eight studies (17%), unclear for 25 (52%),
and high for 15 (31%). Twenty four studies only
included infants aged less than 1 year.
Outpatients
Figure 2 displays the effect estimates for the primary
outcome of admission rates from the emergency
department (day 1) for the different direct compari-
sons. The results were statistically significant for only
one comparison, showing a reduction of 33% for adre-
naline compared with placebo (pooled risk ratio 0.67,
Table 2 |Results of direct comparisons for change in clinical score among outpatients
Comparison Time point
No of studies
(No of patients)
Standardised mean
difference (95% CI) I
2 (%)
Steroid v placebo
1 hour 4 (1006) −0.04 (−0.16 to 0.09) 0
2 hour 3 (214) −0.17 (−0.55 to 0.21) 43
3-6 hours 4 (808) −0.14 (−0.50 to 0.21) 68
12-24 hours 1 (69) 0.13 (−0.51 to 0.76) 36
3-10 days 4 (224) −0.20 (−0.61 to 0.21) 55
Steroid v adrenaline
1 hour 2 (442) 0.31 (0.12 to 0.50)* 0
2 hours 1 (45) 0.35 (−0.27 to 0.98) NA
3-6 hours 1 (45) 0.42 (−0.20 to 1.05) NA
Steroid v salbutamol
1 hour 1 (45) 0.65 (0.01 to 1.28)† NA
2 hours 1 (45) 0.36 (−0.27 to 0.98) NA
3-6 hours 1 (45) 0.70 (0.06 to 1.34)† NA
Adrenaline v placebo
1 hour 4 (900) −0.45 (−0.66 to −0.23)* 40
2 hours 1 (30) −0.83 (−1.58 to −0.08)* NA
Adrenaline v salbutamol
1 hour 6 (248) −0.11 (−0.36 to 0.14) 0
2 hours 4 (207) −0.09 (−0.37 to 0.18) 0
12-24 hours 1 (69) −0.21 (−0.86 to 0.44) 41
3-10 days 1 (69) −0.50 (−0.98 to −0.02)* 0
Salbutamol v placebo
1 hour 8 (565) −0.49 (−0.96 to −0.01)† 86
2 hours 2 (100) −0.04 (−1.07 to 0.99) 84
3-6 hours 1 (60) −0.79 (−2.53 to 0.95) 90
Ipratropium v placebo 2 hours 1 (69) −0.14 (−0.61 to 0.33) NA
Adrenaline and dexamethasone
v placebo
1 hour 1 (399) −0.34 (−0.54 to −0.14)‡ NA
Adrenaline and dexamethasone
v salbutamol
2 hours 1 (35) −0.17 (−0.87 to 0.52) NA
12-24 hours 1 (35) 0.00 (−0.70 to 0.70) NA
3-10 days 1 (35) −1.22 (−1.98 to −0.46)‡ NA
Steroid and salbutamol
v placebo
1 hour 1 (30) −0.34 (−1.75 to 1.07) NA
2 hours 1 (30) −0.67 (−2.04 to 0.70) NA
3-6 hours 1 (30) −1.08 (−2.43 to 0.27) NA
Steroid and salbutamol
v adrenaline
1 hour 1 (30) 0.36 (−0.36 to 1.08) NA
2 hours 2 (64) 0.25 (−0.26 to 0.77) 0
12-24 hours 1 (34) 0.30 (−0.43 to 1.02) NA
3-10 days 1 (34) −0.16 (−0.88 to 0.56) NA
NA=not applicable.
*Results favour adrenaline.
†Results favour salbutamol.
‡Results favour combined adrenaline and dexamethasone.
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 5 of 1095% confidence interval 0.50 to 0.89). The strength of
evidence for this finding was considered moderate
owing to lack of precision (see web extra appendix
B). The number needed to treat based on the average
baselineriskofadmissionfromallstudies(20%)was15
(95% confidence interval 10 to 45). The number
neededtotreatrangedfrom4(95%confidenceinterval
3 to 12, baseline risk 75%) to 20 (13 to 59, baseline risk
15%). The results were sensitive to risk of bias: when
studies with an unclear risk of bias were removed, the
pooled estimate for the two studies (n=842) at low risk
of bias was no longer statistically significant (pooled
risk ratio 0.77, 0.56 to 1.07). Subgroup analyses
showed non-statistically significant differences
between studies combining adrenaline with steroids
that followed a protocol (pooled risk ratio 0.74, 0.45
to 1.23; one study, n=400) compared with those that
did not follow a protocol (0.62, 0.40 to 0.94; four stu-
dies, n=520; ratio of risk ratios 1.19, 0.61 to 2.33). An
effectofasimilarmagnitudewasshownwithcombined
adrenaline and dexamethasone compared with pla-
cebo (35%), but this did not reach significance
(P=0.07) (pooled risk ratio 0.65, 0.4 to 1.05; one
study, n=400).
Figure 3 illustrates the comparisons and number of
studies for each that were examined in the mixed treat-
mentcomparisonforadmissionsatday1.Crossvalida-
tion showed that the results from the mixed treatment
analysis were consistent with direct evidence not differ-
ing significantly from indirect evidence for any of the
paired comparisons where direct evidence was avail-
able. The mixed treatment comparison identified
adrenaline alone and combined adrenaline and dexa-
methasone as the interventions with the highest prob-
ability of being most effective, with about half the odds
of being admitted from the emergency department
compared with placebo (fig 4). The odds ratios were
0.48 (95% credibility interval 0.18 to 1.01) for adrena-
line alone and 0.52 (0.15 to 1.57) for combined adrena-
line and dexamethasone. Although this provides
evidence on the relative efficacy of the different inter-
ventions, none of the interventions compared with pla-
cebo was statistically significant in this analysis.
Admission rates were also examined up to seven
days after the emergency department visit using direct
comparisons (fig 2). One large study with low risk of
bias showed a statistically significant result for com-
bined adrenaline and dexamethasone, with a 35%
reduction compared with placebo (pooled risk ratio
0.65, 95% confidence interval 0.44 to 0.95); number
needed to treat 11 (95% confidence interval 7 to 76).
Thisresultwasbasedonasinglelargetrialatlowriskof
bias; however, the study was factorial and the authors
did not anticipateor hypothesisean effect for the com-
bined adrenaline and dexamethasonegroup a priori.
16
The strength of evidence for this finding, based on the
modified GRADE system, is considered low, as evi-
dence came from only one study with relatively few
events. The overall results for steroids compared with
placebo and for adrenaline compared with placebo
were not statistically significant; however, subgroup
analyses examining use of bronchodilators or steroids
that followed a protocol showed some important
effects (data not shown). Specifically, adrenaline
along with steroids that followed a protocol compared
with placebo and steroidsshowed a statistically signifi-
cant reduction of 33% (pooled risk ratio 0.67, 95%
confidence interval 0.45 to 0.98). Also, steroids with
use of bronchodilators (adrenaline or salbutamol) that
followed a protocol compared with placebo and
bronchodilators showed a similar magnitude of effect
(32%) but did not reach statistical significance (pooled
risk ratio 0.68, 95% confidence interval 0.44 to 1.05;
P=0.08).
Mixed treatment comparison for admissions up to
day 7identifiedsteroidswithbronchodilators (adrena-
lineorsalbutamol)astheinterventionswiththehighest
probability of being most effective, although the cred-
ibility intervals were wide and do not rule out the pos-
sibility of no effect (see web extra appendix D).
Table 2presentstheresultsfrompairwisemeta-ana-
lysis for change in clinical score. Only nine of the 25
comparisons were statistically significant, and in six of
these adrenaline or adrenaline and dexamethasone
was the preferred treatment. Compared with placebo,
significant benefits were observed for adrenaline at 60
and 120 minutes, combined adrenaline and dexa-
methasone at 60 minutes, and salbutamol at
60 minutes. Adrenaline showed significant benefits
compared with steroids at 60 minutes and salbutamol
at 3-10 days. Combined adrenaline and dexametha-
sone was also superior to salbutamol at 3-10 days.
The other two significant results were from one small
study at unclear risk of bias showing benefits of salbu-
tamol compared with steroids. The results for other
clinical variables were consistent with the findings of
admission rates and clinical score or provided little
additional information (data available from authors).
The incidence of return visits did not differ for any of
the five comparisons where data were available (ster-
oid v placebo, steroid v adrenaline, adrenaline v pla-
cebo, adrenaline v salbutamol, combined adrenaline
and dexamethasone v placebo), although there was
only one or two studies within each comparison for
this outcome.
Adrenaline
Adrenaline + steroid (dexamethasone)
Steroid
Steroid + salbutamol
Placebo
Salbutamol
Salbutamol + ipratropium
0.48 (0.18 to 1.01)
0.52 (0.15 to 1.57)
0.33 (0.33 to 2.05)
0.92 (0.28 to 3.40)
1.00 (not applicable)
1.04 (0.46 to 2.35)
2.17 (0.32 to 14.98)
0.1 0.2 1 5 0.5 2 10
Odds ratio
compared
with placebo
(95% CrI)
Odds ratio
compared
with placebo
(95% CrI)
45.0
38.9
4.5
8.2
0.5
0.4
3.1
Probability
of being best
statistic (%)
Fig 4 | Results of mixed treatment analysis for admissions at day 1, showing probability
ranking and probability of being best statistic
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Figure5displaystheeffectestimatesfortheprimaryout-
come of length of stay for the different direct compari-
sons. Only one comparison was statistically significant,
showing a shorter length of stay for adrenaline com-
pared with salbutamol (mean difference −0.28 days,
95% confidence interval −0.46 to −0.09). The strength
of evidence forthis comparison is considered moderate.
However,thepracticalimplicationsofthisresultneedto
be considered alongside the finding that adrenaline
showed no significant benefit compared with placebo.
Furthermore, this finding was sensitive to risk of bias:
only one study for this comparison was at low risk of
bias and the result was not significant (mean difference
−0.07 days, 95% confidence interval −1.01 to 0.88). The
resultsshowedhighstrengthofevidenceofnodifference
for steroid compared with placebo overall. Subgroup
analyses showed a significant difference for steroids
with use of bronchodilators that followed a protocol
(mean difference −0.12 days, −0.23 to −0.00); however,
the magnitude of effect is not considered clinically
important.
Mixed treatment comparison identified combined
adrenaline and dexamethasone as the preferred treat-
ment (figs 6 and 7). This finding was driven by one
smallstudyathighriskofbias.Theconfidenceinterval
waswideanddidnotruleoutthepotentialfornoeffect.
Moreover, the mixed treatment comparison shows
that none of the interventions examined show clear
efficacy in terms of length of stay among the inpatient
population.
In terms of change in clinical score (table 3), few
differed statistically significantly (5/23 comparisons).
Significantbenefitswereobservedforadrenalinecom-
pared with salbutamol at 60 and 120 minutes, steroids
compared with placebo at 3-6 and 6-12 hours, and sal-
butamol or terbutaline compared with placebo at 6-12
hours. The strength of evidence for these findings is
limitedbyriskofbias,inconsistency(orunknowncon-
sistency owing to limited numbers of studies within
individual comparisons), and lack of precision. The
resultsforotherclinicalsymptomsprovidedlittleaddi-
tional or inconsistent information (data available from
authors). Data for return visits and readmissions were
availableforfourcomparisons(steroidvplacebo,adre-
nalinevplacebo,adrenalinevsalbutamol,and salbuta-
mol v placebo). No significant differences were found
although only one or two studies were available for
each comparison.
Harms
Sixteen studies provided data on short term adverse
effects (see web extra appendix E). No studies exam-
ined, or were necessarily designed to examine, long
term adverse effects, such as cognitive injury. The
types of adverse effects that were most commonly
searched for (or reported on) included pallor, vomit-
ing, tremors, hypertension, tachycardia, and infec-
tions. In general, the incidence of adverse effects was
low and no important differences were observed
between groups across the studies.
DISCUSSION
Previous syntheses provide little conclusive evidence
to support the choice of different treatment options in
the acute management of bronchiolitis. By examining
steroids and bronchodilators in a single systematic
review and supplementing the standard meta-analysis
with mixed treatment comparisons, this review pro-
vides some important directions for clinical practice
and future research. Adrenaline seems to be beneficial
for short term outcomes among outpatients, including
admission rates from the emergency department.
Furthermore, adrenaline combined with dexametha-
sone showed longer term effects, reducing admission
Table 3 |Results of direct comparisons for change in clinical score among inpatients by
comparison
Comparison Time point
No of studies
(No of patients)
Standardised mean
difference (95% CI) I
2 (%)
Steroid v placebo
3-6 hours 1 (174) −1.03 (−1.87 to −0.19)* NA
6-12 hours 3 (269) −0.62 (−1.00 to −0.23)* 10
12-24 hours 3 (264) −0.28 (−0.66 to 0.09) 41
1-3 days 4 (271) −0.53 (−1.14 to 0.08) 70
Adrenaline v placebo 1 hour 2 (232) −0.04 (−0.49 to 0.40) 46
Adrenaline v salbutamol
1 hour 4 (248) −0.79 (−1.45 to −0.13)† 79
2 hours 1 (140) −0.52 (−0.86 to −0.18)† NA
Salbutamol or terbutaline
v placebo
1 hour 5 (223) −0.20 (−0.76 to 0.35) 76
2 hours 2 (68) −0.78 (−2.53 to 0.98) 91
3-6 hours 1 (89) −0.20 (−0.61 to 0.22) 0
6-12 hours 2 (136) −0.81 (−1.21 to −0.40)‡ 25
12-24 hours 2 (136) −0.21 (−0.62 to 0.20) 31
1-3 days 3 (195) −0.06 (−0.47 to 0.36) 53
Ipratropium v placebo
1 hour 1 (89) −0.11 (−0.53 to 0.31) 0
3-6 hours 1 (89) 0.06 (−0.39 to 0.51) 13
6-12 hours 2 (134) −0.21 (−0.80 to 0.37) 65
12-24 hours 3 (193) −0.27 (−0.61 to 0.06) 27
1-3 days 3 (193) 0.05 (−0.38 to 0.49) 56
Salbutamol v ipratropium
1 hour 1 (43) −0.22 (−0.82 to 0.38) NA
3-6 hours 1 (43) 0.20 (−0.40 to 0.80) NA
6-12 hours 3 (123) 0.16 (−0.40 to 0.72) 59
12-24 hours 4 (183) −0.24 (−0.54 to 0.06) 3
1-3 days 4 (183) −0.10 (−0.39 to 0.19) 0
NA=not applicable.
*Results favour steroid.
†Results favour adrenaline.
‡Results favour salbutamol or terbutaline.
Length of stay (days)
  Steroid v placebo
  Adrenaline v placebo
  Adrenaline v salbutamol
  Salbutamol or terbutaline v placebo
  Ipratropium v placebo
  Salbutamol v ipratropium
-0.18 (-0.39 to 0.04)
-0.35 (-0.87 to 0.17)
-0.28 (-0.46 to -0.09)
0.11 (-0.26 to 0.48)
-0.04 (-0.53 to 0.45)
0.13 (-0.33 to 0.58)
8/633
2/292
4/261
6/346
2/148
3/137
-1.0 -0.5 0 0.5 1.0
Comparisons (A v B) Mean difference
(95% CI)
Mean difference
(95% CI)
No of studies/
No of patients
16
0
0
0
26
0
I2 (%)
Favours A Favours B
Fig 5 | Results from meta-analysis of direct comparisons for length of stay in inpatients. Only
comparisons with quantitative results are shown
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visit. The strength of evidence for this reduction in
admission rates was considered low based on the
GRADE system, largely because it came from a single
trial; however, recent empirical evidence suggests that
relianceonevidencefromasingleprecisetrialthathas
beencarriedoutwellisreasonable.
32Theeffectiveness
of these interventions is supported by positive benefits
insomeofthesecondaryoutcomemeasures,including
short term changes in clinical score, with no observed
concerns about short term safety. For inpatients, none
of the interventions examined showed clear benefits
for length of stay. Adrenaline showed some significant
improvements for short term changes in clinical score,
whereassteroidsandsalbutamolshowedbenefitscom-
pared with placebo over the longer follow-up periods
(3-6 and 6-12 hours).
Interpretation of findings
The magnitude and timing of observed effects of adre-
nalineandsteroidsaresupportedthroughtheirknown
mechanisms of actions. Adrenaline has been shown to
improve short term clinical variables, but its effect on
admission rates was unclear, mostly due to underpow-
ered studies.
33 We did not confirm concerns that the
early benefit shown might result in a later increase in
admissions or return visits.
34 The longstanding claim
that the α adrenergic vasoconstricting and oedema
reducing activity of adrenaline may confer advantage
over β adrenergic only drugs was supported by direct
andindirectcomparisonssuggestingsomebenefitover
salbutamol.
35 Findings also indicate that previous con-
flicting results on the use of steroids may be partially
explained by interaction with bronchodilators. Our
analysis clearly excludes a clinically relevant stand
alone effect of steroids but shows additive effects
when combining a long action steroid such as dexa-
methasone with use of bronchodilators that follow a
protocol. It is recognised that the immune response
plays a significant part in the pathogenesis of
bronchiolitis,
36 although the biological action of anti-
inflammatory interventions may be limited.
37 Clinical
synergism between steroids and bronchodilators is a
major topic in the long term treatment of asthma and
chronic obstructive pulmonary disease.
38 Findings
from translational research show a two way molecular
interaction between these drugs, including β2 agonist
stimulated steroid mediated gene transcription, and a
steroid induced increase in the transcription of the β2
receptor gene.
39 Whether these mechanisms are
involved in the treatment of acute bronchiolitis, and
the contribution of specific types and doses of bronch-
odilators and steroids, is unknown.
Another outstanding problem is the difference in
observed effects between inpatient and outpatient
populations.Adrenalineshowsbenefitsforoutpatients
butnotforinpatients.Thismaybeattributabletoshort
term compared with long term response or character-
istics of the patients (for example, responders v non-
responders)orillness(forexample,timingandseverity
of infection).
Safety concerns exist about the widespread use of
adrenaline and steroids in young children with viral
wheezing, particularly with repeated high doses.
4041
Our results do not suggest any serious or frequent
short term expected or unexpected harms from any
of the studied interventions in infants with bronchioli-
tis in the absence of comorbidities. However, our
safety analysis is based on randomised trials, which
often have limited power to detect important differ-
ences owing to the infrequent occurrence of events.
Data from trials and observational studies in croup
confirm a favourable short term safety profile.
42 Long
term problems raised by the use of steroids in prema-
turity include effects on adrenal function, cardio-
vascular responses, somatic and lung growth, and
neurodevelopment.
43-47 Evidence is, however, scarce
on the effects for short term use in otherwise healthy
term infants,
42 and none of these were studied in
included trials.
Limitations of existing evidence
Our strength of evidence assessments provide clarity
around the limitations of this body of evidence and
direction for future research. Two key factors affected
the strength of evidence: potential risk of bias in the
Placebo
Steroid
Salbutamol
+ steroid
Ipratropium
Ipratropium
+ salbutamol
Ipratropium
+ salbutamol + steroid
Adrenaline
Adrenaline
+ steroid
Salbutamol Salbutamol Salbutamol Salbutamol
1 1
1
1
6
No of comparisons
4
3
2
1
1
Fig 6 | Comparisons (19 studies) contributing to mixed
treatment analysis for length of stay. Numerals within figure
are studies at low risk of bias (two in total)
Adrenaline + steroid
Steroid + salbutamol + ipratropium
Steroid
Adrenaline
Ipratropium
Placebo
Salbutamol
Salbutamol + ipratropium
Steroid + salbutamol
-1.01 (-5.29 to 3.01)
-0.43 (-2.03 to 1.23)
-0.35 (-0.76 to 0.08)
-0.28 (-0.71 to 0.12)
-0.10 (-0.62 to 0.43)
0.00 (not applicable)
0.04 (-0.33 to 0.41)
0.19 (-0.54 to 0.96)
0.41 (-0.57 to 1.38)
-5.0 -2.0 0 2.5 5.0
Mean difference
in length of stay
(days) compared with
placebo (95% CrI)
Mean difference
in length of stay
(days) compared with
placebo (95% CrI)
54.2
25.1
11.1
6.1
2.0
0.01
0.02
0.3
1.0
Probability
of being best
statistic (%)
Fig 7 | Results of mixed treatment analysis for length of stay, showing probability ranking and
probability of being best statistic
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outcomes and comparisons, which resulted in impre-
cise estimates and unknown consistency of estimates
across studies. Risk of bias was high due to potential
selective outcome reporting, incomplete outcome
data, and lack of blinding. Reporting of sequence gen-
eration and allocation concealment was often unclear.
Sparsity of data was a result of few studies making the
samecomparisonsaswellasvariabilityinthechoiceof
outcomes and timing of outcome assessments. The
message around consistency and relevance of out-
comes is not new for this discipline.
4849 Further work
to define clinically important efficacy and safety out-
comes for bronchiolitis is ongoing.
Implications for research
Future research should focus on areas where there is
somesuggestionofbenefit(significantorclosetosignif-
icantresults in direct meta-analysiswitha magnitudeof
effectthatisclinicallymeaningful,orrelativesuperiority
in mixed treatment comparisons) but the strength of
evidence is moderate or low—that is, future research
may change our confidence in the estimate and may
change the estimate. Based on this review, adrenaline
and combined adrenaline and dexamethasone seem to
beemergingasthepreferredtreatmentsforoutpatients.
This review found no clear advantage of steroids or
bronchodilators among inpatients. This information
should guide the choice of comparators, including
their dose and combinations, for future large trials.
Strengths and limitations of the review
Thisreviewhasfollowedcurrentmethodologicalstan-
dardsforthesynthesisofevidence.Moreover,wehave
incorporated new methods of analysis to simulta-
neously compare the different interventions and to
provide greater clarity around their relative benefits.
Limitations of mixed treatment comparisons have
beencited,specificallyassumptionsofsufficienthomo-
geneity to combine data and generalisability to indivi-
dual patients.
20 The influence of age, history of
wheezing episodes, and wheezing phenotype has led
to repeated controversies in this subject,
4050 and it is
not yet clear how best to approach these problems at
a trial and systematic review level. We focused on first
time wheezing so results could be directly pertinent to
infants with typical viral bronchiolitis. We searched
extensively for relevant literature and included all stu-
diesregardlessoflanguageofpublication.Wearecon-
fident that this review represents the most
comprehensive synthesis currently available for the
two most promising treatments for bronchiolitis, ster-
oids and bronchodilators.
Conclusion
Uncertaintyabouttheoptimalmanagementofbronch-
iolitis is underscored by evidence showing substantial
variation in practice, even within homogenous clinical
settings. Current clinical practice guidelines recom-
mend only supportive measures based on the absence
of convincing evidence for any other approach. This
systematicreviewshowsabenefitofadrenalineforout-
comes of most clinical relevance among outpatients.
Moreover, adrenaline is shown to be safe and is
relatively inexpensive. Some evidence exists for a
beneficial synergistic effect of adrenaline and dexa-
methasone. Further research of this combined treat-
ment is needed among outpatients. For inpatients,
none of the interventions examined showed clear ben-
efitsforlengthofstay.Consensusonthemostclinically
important outcomes and consistency in their applica-
tion will yield stronger evidence for this important
source of morbidity among young children.
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